Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Mónica Galli et al.|The Lancet Oncology|2019Cited by 386
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.Gilles Salles, Paolo Ghia, Bipinkumar Amin et al.|Journal of Clinical Oncology|2014Cited by 10